|
| Press Releases |
|
 |
|
| Wednesday, May 9, 2018 |
|
|
Helsinn Group announces the launch of the IV formulation of AKYNZEO(R) (fosnetupitant/palonosetron) in the United States |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the intravenous formulation of AKYNZEO(R) (a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) for injection has been launched in the United States by its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc.. more info >> |
|
| Friday, April 20, 2018 |
|
|
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of AKYNZEO(R) (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing CINV. more info >> |
|
| Tuesday, April 17, 2018 |
|
|
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy |
| Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma focused on oncology and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announce that they are collaborating on the development of an investigational highly-selective RET inhibitor TAS0286/HM05, being evaluated in non-small cell lung cancer and other carcinomas. more info >> |
|
| Wednesday, March 28, 2018 |
|
|
Helsinn Healthcare S.A.: Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced |
| Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announced that Lorenzo Pradella of GreenBone Ortho, srl and Gitte Pedersen of Genomic Expression, Inc. have been chosen as winners of the first ever Lyfebulb-Helsinn Innovation Awards in Oncology. more info >> |
|
| Friday, March 2, 2018 |
|
|
Helsinn Healthcare S.A.: Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology |
| Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announce the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. more info >> |
|
| Tuesday, October 17, 2017 |
|
|
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China |
| Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces the approval of Helsinn Pharmaceuticals (Beijing) Co. Ltd., Shanghai branch, on August 7, 2017 by the Shanghai Administration for Industry and Commerce with a 30-year term. The full address and contact details of the Shanghai branch are found at the end of this announcement. more info >> |
|
| Friday, September 9, 2016 |
|
|
Helsinn and PatientsLikeMe Announce Results of NSCLC Patient Survey on Weight Loss |
| Helsinn Therapeutics (U.S.) Inc., the pharmaceutical group focused on building quality cancer care, and patient network PatientsLikeMe have unveiled findings from an online survey that captured experiences and insights about unintended weight loss and its burden among 95 patients living with non-small cell lung cancer. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
New HKTDC Chairman Frederick Ma keen to promote Hong Kong as best partner for global enterprises
Jun 10, 2025 20:25 HKT/SGT
|
|
|
爆款IPO前瞻：「香水第一股」穎通控股強勢登場！港股IPO再現黃金賽道 龍頭勢掀「嗅覺經濟」新浪潮
Jun 10, 2025 19:10 HKT/SGT
|
|
|
爆款IPO前瞻：“香水第一股”颖通控股强势登场！港股IPO再现黄金赛道 龙头势掀“嗅觉经济”新浪潮
Jun 10, 2025 19:10 HKT/SGT
|
|
|
U.S. Polo Assn. Returns as Official Apparel and Jersey Partner for Chestertons Polo in the Park in Downtown London
Jun 10, 2025 19:00 HKT/SGT
|
|
|
Supercomputer Fugaku retains first place worldwide in Graph500 rankings
Jun 10, 2025 19:47 JST
|
|
|
ダイムラートラック、三菱ふそう、日野、トヨタ、三菱ふそうと日野の統合に関する最終合意を締結
Jun 10, 2025 16:30: JST
|
|
|
聯想控股副總裁于浩：在技術變革中錨定「長期主義」
Jun 10, 2025 15:37 HKT/SGT
|
|
|
联想控股副总裁于浩：在技术变革中锚定"长期主义"
Jun 10, 2025 15:28 HKT/SGT
|
|
|
Ai sẽ là người đầu tiên ghi danh vào lịch sử với tư cách là Nhà Vô Địch Thế Giới đầu tiên?!
Jun 10, 2025 14:00 HKT/SGT
|
|
|
Siapakah yang akan mengukir nama dalam sejarah sebagai "Juara Dunia Pertama"!
Jun 10, 2025 14:00 HKT/SGT
|
|
|
Siapakah yang akan mengukir namanya dalam sejarah sebagai “Juara Dunia Pertama”!
Jun 10, 2025 14:00 HKT/SGT
|
|
|
誰將成為名留青史的「初代世界冠軍」！
Jun 10, 2025 14:00 HKT/SGT
|
|
|
UK MOD Signs Protector Support Contract with GA-ASI
Jun 10, 2025 06:00 HKT/SGT
|
|
|
SRKay Consulting Group Releases Research Report: 'From Legal Frameworks to Successful Operations'--A Strategic Playbook for India Market Entry
Jun 9, 2025 17:00 HKT/SGT
|
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025
Jun 9, 2025 12:52 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
